^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    3d
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (clinicaltrials.gov)
    P1/2, N=202, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • YL201
    4d
    QLC5508-201: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=444, Recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C
    9d
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P1 trial • First-in-human
    10d
    A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=180, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed
    Trial completion
    14d
    DB-1311-O-1001: A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=862, Recruiting, DualityBio Inc. | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Sep 2027 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD276 (CD276 Molecule)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12
    |
    Xtandi (enzalutamide) • abiraterone acetate • itraconazole • BNT324 • ritonavir
    17d
    A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=116, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P1/2 trial
    |
    MHB088C
    18d
    A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=260, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yidafan (ivonescimab) • YL201
    18d
    A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial primary completion date: Jul 2025 --> Jul 2027
    Trial primary completion date
    23d
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (clinicaltrials.gov)
    P1/2, N=170, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    1m
    An open-label, multicenter Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics, and efficacy of QLC5508 injection combined therapy in patients with advanced solid tumors (ChiCTR2500110587)
    P1/2, N=414, Not yet recruiting, Shanghai East Hospital; Qilu Pharmaceutical Co.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C • levoleucovorin calcium
    1m
    An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients with Advanced Solid Tumors. (ChiCTR2500110610)
    P1, N=150, Not yet recruiting, Zhejiang Cancer Hospital; Hangzhou DAC Biotechnology Co.,Ltd.
    New P1 trial • First-in-human
    1m
    Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities. (PubMed, Curr Oncol)
    Novel agents such as tarlatamab (DLL3-targeting) and ifinatamab deruxtecan (B7-H3-targeting) have shown encouraging efficacy in early-phase trials, though predictive markers remain elusive. A multi-dimensional approach combining tissue, blood, and immune profiling is essential to advance precision oncology in SCLC and improve patient selection for emerging therapies.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    ifinatamab deruxtecan (DS-7300) • Imdelltra (tarlatamab-dlle)